Neoadjuvant nivolumab for patients with non-metastatic high risk kidney cancer
A recent phase 1 trial showed that treatment with nivolumab before surgery (neoadjuvant treatment) was tolerable in patients with high-risk clear cell renal cell carcinoma (RCC) that had not spread. These results were presented at the 21st Annual Meeting of the Society of Urologic Oncology (SUO). The study was a phase 1 trial that looked […]